Evidence map›Paper›PMID 31231915›Full record

ArticleProteomics2019

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer.

Sunag Udupa, Stephanie Nguyen, Giang Hoang, Tu Nguyen, Addison Quinones, Khoa Pham, Ryoichi Asaka, Kiet Nguyen, Cissy Zhang, Amira Elgogary and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Preparative Biocatalytic Synthesis of α-Ketoglutaramate.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Sunag UdupaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Stephanie NguyenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Giang HoangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Tu NguyenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Addison QuinonesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Khoa PhamDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Ryoichi AsakaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Kiet NguyenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Cissy ZhangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Amira ElgogaryDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Jin G JungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Qingguo XuDepartment of Ophthalmology and Wilmer Eye Institute Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Jie FuDepartment of Ophthalmology and Wilmer Eye Institute Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Justin HanesDepartment of Ophthalmology and Wilmer Eye Institute Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Arthur J L CooperDepartment of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, 10595, USA.
Anne LeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.ORCID 0000-0002-2958-8149
Johns Hopkins University · USNew York Medical College · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Probing the Connections between Monosaccharide Analogs, Sialic Acid Metabolism, aR01CA112314 · NCI · JOHNS HOPKINS UNIVERSITY · PI YAREMA, KEVIN J · 2005 to 2022
$4.5M
Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer TherapyR01CA193895 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S., LE, ANNE · 2016 to 2020
$2.1M
Thermo-Scientific Q Exactive Plus Orbitrap LC-MS/MS SystemS10OD025226 · OD · JOHNS HOPKINS UNIVERSITY · PI LE, ANNE · 2018 to 2018
$562k
Profiling Pancreatic Cancer Metabolism and Tumor Microenvironment for TherapyR21CA169757 · NCI · JOHNS HOPKINS UNIVERSITY · PI LE, ANNE · 2013 to 2014
$382k
NCATS NIH HHS UL1 TR001079NCI NIH HHS R01 CA112314NCI NIH HHS R01-CA112314NCI NIH HHS R01 CA193895NCI NIH HHS R01-CA193895NCI NIH HHS R21 CA169757NCI NIH HHS T32 CA193145NIH HHS 1S10OD025226-01NIH HHS R01-CA112314NIH HHS R01-CA193895NIH HHS S10 OD025226NIH HHS UL1 TR001079
6 · The paper itself

Abstract

The targeting of glutamine metabolism specifically via pharmacological inhibition of glutaminase 1 (GLS1) has been translated into clinical trials as a novel therapy for several cancers. The results, though encouraging, show room for improvement in terms of tumor reduction. In this study, the glutaminase II pathway is found to be upregulated for glutamate production upon GLS1 inhibition in pancreatic tumors. Moreover, genetic suppression of glutamine transaminase K (GTK), a key enzyme of the glutaminase II pathway, leads to the complete inhibition of pancreatic tumorigenesis in vivo unveiling GTK as a new metabolic target for cancer therapy. These results suggest that current trials using GLS1 inhibition as a therapeutic approach targeting glutamine metabolism in cancer should take into account the upregulation of other metabolic pathways that can lead to glutamate production; one such pathway is the glutaminase II pathway via GTK.

Indexed as

Cell Line, TumorCell ProliferationEnzyme InhibitorsGene Expression Regulation, NeoplasticGlutamic AcidGlutaminaseGlutamineHumansLyasesMetabolic Networks and PathwaysPancreatic NeoplasmsTransaminasesEnzyme InhibitorsGLS protein, humanGlutamic AcidGlutaminaseGlutamineglutamine - phenylpyruvate transaminaseglutamine-pyruvate aminotransferaseLyasesTransaminasesglutaminase 1 inhibitionglutaminase II pathwayglutamine transaminase K

Identifiers

PMID31231915
PMCPMC6851409
OpenAlexW2954950011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.